Bavarian Nordic data shows booster shot protects against Omicron

A phase II study has demonstrated that the biotech firm’s Covid-19 vaccine candidate still provides a high level of protection against Omicron, although antibody levels were lower compared to all previously reported variants.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Danish biotech firm Bavarian Nordic has demonstrated in a phase II trial that vaccine candidate ABNCoV2 provides protection against the currently dominant Covid-19 variant, Omicron, the company announced in a Thursday press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs